两家中国公司合作伙伴FZ002-037开发了一种新的疼痛治疗,这是中国第一家临床试验的SSTR4激动剂公司。 Two Chinese companies partner to develop a new pain treatment, FZ002-037, the first SSTR4 agonist in clinical trials in China.

两家中国制药公司, 广州费米昂科技和Simcere制药, 已经合作开发FZ002-037, 一种新的疼痛治疗. Two Chinese pharmaceutical companies, Guangzhou Fermion Technology and Simcere Pharmaceutical, have partnered to develop FZ002-037, a new pain treatment. 该药物是中国开发的首种STRI4激动剂,也是在全球范围进行临床试验的第二种。 This drug is the first SSTR4 agonist developed in China and the second globally to reach clinical trials. 它具有治疗各种疼痛条件的潜力,包括糖尿病神经病。 It has potential for treating various pain conditions, including diabetic neuropathy. 先声药业获得了在大中华区开发和销售该药物的独家权利，而 Fermion 将从未来的销售中获得付款和特许权使用费。 Simcere gains exclusive rights to develop and sell the drug in Greater China, while Fermion will receive payments and royalties from future sales.